Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Core Insights - Ocugen, Inc. is hosting a conference call and live webcast to discuss data from the OCU410 Phase 2 ArMaDa clinical trial, focusing on patients who have completed one year since treatment [1] - The conference call is scheduled for January 15, 2026, at 8:30 a.m. ET, featuring key opinion leaders and Ocugen's executive leadership [1][2] Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing therapies for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [3]